Sanofi Income Taxes 2010-2024 | SNY
Sanofi annual/quarterly income taxes history and growth rate from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
- Sanofi income taxes for the quarter ending September 30, 2024 were $0.810B, a 32.25% increase year-over-year.
- Sanofi income taxes for the twelve months ending September 30, 2024 were $1.643B, a 30.46% decline year-over-year.
- Sanofi annual income taxes for 2023 were $1.734B, a 17.96% decline from 2022.
- Sanofi annual income taxes for 2022 were $2.114B, a 14.66% increase from 2021.
- Sanofi annual income taxes for 2021 were $1.843B, a 11% decline from 2020.
Sanofi Annual Income Taxes
(Millions of US $) |
| 2023 |
$1,734 |
| 2022 |
$2,114 |
| 2021 |
$1,843 |
| 2020 |
$2,071 |
| 2019 |
$156 |
| 2018 |
$568 |
| 2017 |
$1,946 |
| 2016 |
$1,467 |
| 2015 |
$787 |
| 2014 |
$1,557 |
| 2013 |
$1,013 |
| 2012 |
$1,458 |
| 2011 |
$634 |
| 2010 |
$1,649 |
| 2009 |
$1,902 |
Sanofi Quarterly Income Taxes
(Millions of US $) |
| 2024-09-30 |
$810 |
| 2024-06-30 |
$322 |
| 2024-03-31 |
$178 |
| 2023-12-31 |
$333 |
| 2023-09-30 |
$613 |
| 2023-06-30 |
$295 |
| 2023-03-31 |
$493 |
| 2022-12-31 |
$962 |
| 2022-09-30 |
$605 |
| 2022-06-30 |
$173 |
| 2022-03-31 |
$373 |
| 2021-09-30 |
$718 |
| 2021-06-30 |
|
| 2021-03-31 |
$487 |
| 2020-09-30 |
$573 |
| 2020-03-31 |
$479 |
| 2019-09-30 |
$298 |
| 2019-03-31 |
$290 |
| 2018-03-31 |
$230 |
| 2017-12-31 |
$803 |
| 2017-09-30 |
$484 |
| 2017-06-30 |
$301 |
| 2017-03-31 |
$358 |
| 2016-12-31 |
$396 |
| 2016-09-30 |
$513 |
| 2016-06-30 |
$429 |
| 2016-03-31 |
$129 |
| 2015-09-30 |
$303 |
| 2015-06-30 |
$574 |
| 2014-06-30 |
$480 |
| 2013-06-30 |
$59 |
| 2012-06-30 |
$479 |
| 2012-03-31 |
$650 |
| 2011-12-31 |
$-590 |
| 2011-09-30 |
$564 |
| 2011-06-30 |
$292 |
| 2011-03-31 |
$368 |
| 2010-12-31 |
$-117 |
| 2010-09-30 |
$470 |
| 2010-06-30 |
$618 |
| 2010-03-31 |
$679 |
| 2009-12-31 |
$364 |
| 2009-09-30 |
$617 |
| 2009-06-30 |
$356 |
| 2009-03-31 |
$565 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$122.552B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
